Clinical Efficacy of Bifidobacterium Quadripartitum Active Tablets Combined with Antibiotics in Severe Pneumonia Children and their Impact on Gut Microbiota and Inflammatory Cytokine Levels
Abstract 【Objective】To investigate the clinical efficacy of Bifidobacterium quadruple active tablets combined with antibiotics in severe pneumonia (SP) children on gut microbiota,pulmonary ultrasound score(LUS) and inflammatory cytokine levels. 【Methods】A total of 102 children with SP admitted to our hospital from January 2021 to August 2023 were selected and randomly divided into the control group (conventional symptomatic treatment and antibiotic treatment) and the observation group (combined with Bifidobacterium quadruple viable tablets on the basis of the control group) using a random number table method, with 51 cases in each group. Two groups were compared in terms of clinical efficacy, pre-and post-treatment lung function indicators [forced expiratory volume in one second (FEV1), vital capacity (VC), LUS], gut microbiota [Escherichia coli, Bifidobacterium, Enterococcus, Lactobacillus], inflammatory factors [interleukin (IL-10), C-reactive protein (CRP), soluble intercellular adhesion molecule-1 (sICAM-1), tumor necrosis factor alpha (TNF-α)] levels. 【Results】The total effective rate of the observation group was higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, FEV1, and VC in both groups were higher than before treatment, LUS was lower than before treatment, the difference was statistical significance in two groups(P<0.05); The levels of Bifidobacterium and Lactobacillus in both groups were higher than before treatment, while the levels of Enterococcus and Escherichia coli were lower than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05); The levels of IL-10 in both groups were higher than before treatment, while the levels of CRP, sICAM-1, and TNF-α were lower than before treatment. The difference between the observation group and the control group was statistically significant (P<0.05). 【Conclusion】The combination of Bifidobacterium quadruple active tablets and antibiotics has good clinical efficacy in treating SP children, inhibiting inflammatory reactions, and improving lung function in children.
CHEN Yajun,XIE Junqi,YUN Liangliang. Clinical Efficacy of Bifidobacterium Quadripartitum Active Tablets Combined with Antibiotics in Severe Pneumonia Children and their Impact on Gut Microbiota and Inflammatory Cytokine Levels[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(8): 1182-1184.
2024, Vol. 41 
